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Background: Fluticasone furoate/vilanterol (FF/VI) is an inhaled corticosteroid/long-acting
beta2-agonist (ICS/LABA), recently approved as once-daily maintenance therapy for COPD.
We compared the lung function effects of FF/VI with those of twice-daily fluticasone propio-
nate/salmeterol (FP/SAL).
Methods: Three 12 week studies comparing FF/VI and FP/SAL were conducted. Patients aged
40 years with moderate-to-very severe COPD were randomized to receive double-blind, dou-
ble-dummy FF/VI 100/25 mcg once-daily, or FP/SAL 250/50 mcg twice-daily for 12 weeks
following a 2 week placebo run-in period. The primary endpoint of each study was change from
baseline trough in 0e24 h weighted mean FEV1 (wmFEV1) on Day 84. Safety was also assessed.
Results: In Study 1 (HZC113109) (intent-to-treat n: FF/VIZ 260; FP/SALZ 259), the increase
from baseline in 0e24 h wmFEV1 was significantly greater with FF/VI than FP/SAL (D80 mL,
P < 0.001). In Study 2 (HZC112352) (intent-to-treat n: FF/VIZ 259; FP/SALZ 252) and Study
3 (RLV116974) (intent-to-treat n: FF/VIZ 412; FP/SALZ 416), the increase from baseline in 0ealth Center, Division of Pulmonary, Allergy & Critical Care Medicine, 1900 University Blvd, THT-422,
Birmingham, AL 35294, USA. Tel.: þ1 205 934 5425; fax: þ1 205 934 6229.
du, mdransfield99@msn.com (M.T. Dransfield).
4.05.008
hts reserved.
1172 M.T. Dransfield et al.e24 h wmFEV1 was not significantly greater with FF/VI than FP/SAL (D29 mL, P Z 0.267;
D25 mL, P Z 0.137). The treatment difference was statistically but not clinically significant
in a pooled analysis (D41 mL, P < 0.001). Pooled adverse events (FF/VI 27%; FP/SAL 28%)
and serious adverse events (FF/VI 2%; FP/SAL 3%) were similar between treatments.
Conclusions: Our data suggest that once-daily FF/VI 100/25 mcg provides FEV1 improvement in
COPD that is at least comparable with that conferred by twice-daily FP/SAL 250/50 mcg,
although interpretation is limited by differences in individual study outcomes. The safety pro-
files of FF/VI 100/25 mcg and FP/SAL 250/50 mcg are similar.
Clinical trial registration: clinicaltrials.gov: NCT01323634; NCT01323621; NCT01706328. Glax-
oSmithKline study codes: HZC113109; HZC112352; RLV116974.
ª 2014 Elsevier Ltd. All rights reserved.1 ELLIPTA is a trademark of the GSK group of companies.Introduction
The 2014 update of the Global Initiative for Obstructive
Lung Disease (GOLD) strategy document recommends
combined inhaled corticosteroid/long-acting b2-agonist
(ICS/LABA) as possible maintenance therapy for COPD pa-
tients with severe or very severe airflow limitation (%
FEV1 < 50%) and for those with 2 exacerbations (or 1
exacerbation requiring hospitalization) in the prior year [1].
These recommendations are informed by numerous studies
demonstrating the benefits of ICS/LABA versus LABA alone
on exacerbation rate and lung function in moderate-to-very
severe COPD [2e4].
Previously, ICS/LABA combination therapies were all
dosed twice-daily, as compared with long-acting muscarinic
antagonist and LABA monotherapy, which are available as
once-daily or twice-daily therapies. Dosing frequency has
been suggested to influence adherence to therapy [5],
though it is not the sole factor [6]. It is also known that poor
adherence (even in the setting of a clinical trial) is associ-
ated with adverse outcomes [7].
Fluticasone furoate/vilanterol (FF/VI) is a new ICS/LABA
combination with a once-daily dosing profile. The steroid
component (FF) has greater in vitro anti-inflammatory ac-
tivity than fluticasone propionate (FP) [8], while VI has
superior selectivity for the b2-receptor than other once-
daily LABAs [9]. Once-daily FF/VI at the 100/25 mcg
strength was recently approved in the United States, Can-
ada and Europe for the long-term maintenance treatment
of patients with COPD. FF/VI 100/25 has previously been
shown to improve lung function versus placebo, FF alone
and VI alone over 24 weeks of treatment [10,11]. In addi-
tion, FF/VI 100/25 improves lung function and reduces ex-
acerbations versus VI alone over 52 weeks [12]. The present
analysis describes the results of three 12 week studies that
compared the lung function effects of once-daily FF/VI
100/25 mcg and twice-daily FP/salmeterol (SAL) 250/
50 mcg, in patients with moderate-to-very severe COPD.
Though the approved dose of FP/SAL in the EU is 500/
50 mcg, the 250/50 mcg dose used in these trials represents
the only approved strength for the treatment of COPD in
the United States and Canada.
We hypothesized that the 0e24 h weighted mean (wm)
for FEV1 would be greater with FF/VI 100/25 mcg than with
FP/SAL 250/50 mcg.Methods
Further methodological details are provided in the Online
Supplemental Material.
Patients and ethics
The studies were similar in design and conduct. At
screening, patients (male or female) were 40 years of age
with a clinical history of COPD as defined by ATS/ERS
criteria [13], post-albuterol FEV1/forced vital capacity
(FVC) ratio of 0.70 and FEV1 70% of that predicted using
NHANES III equations [14] and had a 10 pack-year history
of cigarette smoking. Exacerbation frequency was not a
study entry criterion. Patients with a current diagnosis of
asthma were excluded. All patients provided informed
consent. The studies were approved by local or central
ethics review committees, and were conducted in accor-
dance with the Declaration of Helsinki [15] and Good Clin-
ical Practice [16] guidelines.
Study design
These were 12 week, randomized, multi-center, double-
blind, double-dummy, parallel-group, comparative studies.
Study 1 was conducted between March 18 and December 14
2011 at 51 centers in six countries (Czech Republic, Ger-
many, Poland, Romania, Russia, United States). Study 2 was
conducted between March 18 2011 and January 26 2012 at
48 centers in five countries (Italy, South Africa, Spain,
Ukraine, United States). Study 3 was conducted between
October 15 2012 and June 17 2013 at 68 centers in five
countries (Germany, Romania, Russia, Ukraine, United
States).
In each study, eligible patients entered a 2 week, single-
blind, placebo run-in period and, providing they met the
continuation criteria, were randomized (1:1) to FF/VI 100/
25 mcg once-daily in the morning via the ELLIPTA dry
powder inhaler1 (the strength of 100/25 mcg represents an
emitted dose from the dry powder inhaler of 92 mcg of FF
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Diskus/Accuhaler for 12 weeks. Patients were stratified
by reversibility (increase in FEV1 of 12% and 200 mL of
the pre-dose value 10e15 min after four inhalations of al-
buterol) and assigned to study treatment e in accordance
with a randomization schedule generated by the sponsor
using a validated computerised system (RandAll; Glax-
oSmithKline, UK) e using the Registration and Medication
Ordering System (RAMOS; GlaxoSmithKline, UK), an auto-
mated, interactive telephone-based system. Compliance
with study treatment was assessed by reviewing the dose
counters on the inhalers.
Open-label albuterol was supplied to patients for
symptomatic relief during the study. Stable-dose ipra-
tropium and mucolytics were permitted, as was oxygen
therapy for 12 h per day.
Efficacy assessment
The primary efficacy endpoint was the difference between
treatment groups in change from baseline trough in 0e24 h
weighted mean FEV1. This weighted mean FEV1 is deter-
mined by calculating the area under the curve (AUC) during
the 24 h post-dose interval and then dividing that value by
24 h. While results for FEV1 AUC are typically described in
L*hr or mL*hr, this weighted mean approach allows the
results to be presented as a single FEV1 value. Baseline
trough FEV1 was the mean of two assessments of FEV1 made
30 min and 5 min pre-dose on Day 1 (i.e., at the end of the
run-in period). On Day 84, wmFEV1 was calculated from
measures taken 5 min pre-dose then 5, 15, 30, 60 min and 2,
4, 6, 8, 12, 13, 14, 16, 20 and 24 h post-dose. The secondary
efficacy endpoint was time to onset of action on Day 1
(defined as the time to an increase in FEV1 of 100 mL from
baseline over the first 4 h post-dose). An additional sec-
ondary endpoint of change from baseline trough FEV1 after
12 weeks was included for Study 3. Other efficacy endpoints
were change from baseline in FVC on Day 84, the proportion
of patients demonstrating a 100 mL increase in FEV1, and
(in Studies 1 and 2 only) pre-dose inspiratory capacity (IC)
at Day 84 and rescue (albuterol) use.
Safety assessment
Safety and tolerability were assessed by the incidence of
adverse events (AEs) and serious AEs (SAEs), coded using
the Medical Dictionary for Regulatory Activities. AEs of
special interest were pre-defined as those often associated
with either ICS or LABA therapy. COPD exacerbations,
pneumonias, oropharyngeal examinations, clinical chemis-
try and hematology assessments, vital signs and electro-
cardiogram measurements were also recorded.
Statistical analysis
The primary endpoint of 0e24 h wmFEV1 was analyzed in
each study using an analysis of covariance, with baseline
pre-bronchodilator FEV1, reversibility, smoking status,
country, and treatment as covariates. The secondary
endpoint of time to onset was analyzed by log-rank anal-
ysis, stratified by reversibility. A P-value <0.05 for theprimary endpoint was required in order to allow statistical
significance to be inferred for secondary and other end-
points. For this reason, P-values are presented only for
comparisons from which statistical significance can be
inferred; otherwise, point estimates and 95% confidence
intervals (CI) are presented. No such procedure was
employed in the post-hoc analysis of the pooled data.
Sample size calculations for all three studies were based
on the primary endpoint. Based on prior studies of VI [17]
and a putative minimal clinically important difference for
trough FEV1 of 100 mL [18], each study was designed to test
for a 60 mL difference in 0e24 h wmFEV1 between FF/VI
and FP/SAL using a two-sided 5% significance level,
assuming a standard deviation (SD) of 190 mL for Studies 1
and 2. The observed SD for those studies was approximately
240 mL, which was therefore used as the assumed SD for
Study 3. To provide 90% power to detect a 60 mL treatment
difference (see Supplemental Material), assuming a drop-
out rate of 15%, 250 patients per treatment arm were
planned to be randomized in Studies 1 and 2 to achieve a
sample size of 212 evaluable patients in each arm, and 400
patients per treatment arm were planned to be randomized
in Study 3 to achieve a sample size of 338 evaluable pa-
tients per arm.
Results
Patient characteristics
Of 2465 patients screened across the three studies, 1858
were randomized (Fig. 1; Fig. E1). Patients were well
matched between studies and study arms (Table E1). Lung
function at screening and baseline demonstrated, on
average, severely impaired airflow (Table 1). Ninety-one
percent of randomized patients completed treatment; the
primary reasons for withdrawal in both treatment arms
were adverse event and withdrawal of consent. Mean
compliance with treatment was 97% in both treatment
arms in all three studies.
Efficacy: primary outcome
Improvements in 0e24 h wmFEV1 were seen with both FF/VI
100/25 mcg and FP/SAL 250/50 mcg compared with base-
line trough in all three studies and in the pooled analysis
(Table 2). In Study 1, the treatment difference between
FF/VI and FP/SAL was statistically significant (80 mL;
P < 0.001). In Studies 2 and 3, respectively, the difference
(29 mL; 25 mL) were not significant (PZ 0.267; PZ 0.137;
Table E2). In the pooled analysis of all three studies, a small
but statistically significant treatment difference of 41 mL
(P < 0.001) was found (Table 2). The absence of signifi-
cance for the primary treatment comparison in Studies 2
and 3 meant that significance could not be inferred for the
other endpoints in these studies (analysis of pooled data
was performed post hoc and was not subject to any testing
hierarchy). wmFEV1 over 0e4 h, 0e12 h and 12e24 h post-
dose on Day 84 showed significant differences between FF/
VI and FP/SAL on all measures in Study 1, and at 0e4 h and
0e12 h in the pooled analysis. Data obtained from the
comparison of FEV1 measures recorded over all three
Figure 1 CONSORT flowchart for pooled data. Flowcharts for individual Studies 1e3 are provided in Online Supplement.
aComprised: withdrew consent (nZ 34), investigator discretion (nZ 16), adverse event (nZ 5), lost to follow-up (nZ 3), protocol
deviation (n Z 2). bTwo patients in Study 1 were randomized but did not receive any double-blind study medication and were
therefore not included in the ITT population. FF Z fluticasone furoate; FP Z fluticasone propionate; ITT Z intent-to-treat;
SAL Z salmeterol; VI Z vilanterol.
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imum comparable with FP/SAL on lung function (Fig. 2;
Fig. E2).Efficacy: secondary endpoints
Median time to onset (100 mL from baseline) ranged
from 15 to 16 min for FF/VI and 15e30 min for FP/SALTable 1 Demographic and clinical characteristics of the pooled
Pool
FF/V
Demographics
Age, years: mean (SD) 61
Sex, n (%): male 646
Race, n (%): white 899
BMI, kg/m2: mean (SD) 27
COPD duration < 10 yrs, n (%) 663
Current smoker, n (%) 496
Pack-years, mean (SD) 42
Screening lung function (before 2 week placebo run-in)
Post-bronchodilator FEV1, L mean (SD) 1.49
Post-bronchodilator FEV1, % mean (SD) 48
Post-bronchodilator FEV1 reversibility, % mean (SD) 11
Reversible to albuterol, n (%) 246
Post-bronchodilator FEV1/FVC, L mean (SD) 0.51
Baseline lung function (pre-dose on Day 1 of randomization)
Pre-bronchodilator FEV1, L mean (SD) 1.35
Pre-bronchodilator FEV1, % mean (SD) 44
Data for individual Studies 1e3 are provided in the Online Supplemen
BMI Z body mass index; COPD Z chronic obstructive pulmonary dis
furoate; FP Z fluticasone propionate; FVC Z forced vital capacity; Sacross the three studies. For the pooled data, median
time to onset was 15 min for FF/VI and 19 min for FP/SAL
(Fig. 3). Differences in time to onset were statistically
significant in Study 1 (P Z 0.012) and the pooled data
(P Z 0.018) only.
In Study 3, there was no statistically significant
improvement in trough FEV1 between the FF/VI treatment
group and the FP/SAL treatment group (PZ 0.089) after 12
weeks of treatment (Table 2).intent-to-treat population.
ed data
I 100/25 mcg n Z 931 FP/SAL 250/50 mcg n Z 927
(9) 61 (9)
(69) 630 (68)
(97) 898 (97)
(6) 27 (6)
(71) 673 (73)
(53) 522 (56)
(23) 42 (23)
(0.49) 1.48 (0.47)
(12) 48 (12)
(13) 12 (13)
(26) 261 (28)
(0.10) 0.50 (0.10)
(0.50) 1.33 (0.48)
(14) 43 (13)
t.
ease; FEV1 Z forced expiratory volume in 1 s; FF Z fluticasone
AL Z salmeterol; SD Z standard deviation; VI Z vilanterol.
Table 2 Efficacy assessments in individual studies and pooled analysis (intent-to-treat population). FF/VI dosed at 100/
25 mcg; FP/SAL dosed at 250/50 mcg.
Study 1 Study 2 Study 3 Pooled data
FF/VI
n Z 260
FP/SAL
n Z 259
FF/VI
n Z 259
FP/SAL
n Z 252
FF/VI
n Z 412
FP/SAL
n Z 416
FF/VI
n Z 931
FP/SAL
n Z 927
Wm (0e24 h) FEV1, mL on Day 84
LS mean change
from baseline (SE)
174 (15) 94 (16) 142 (18) 114 (18) 168 (12) 142 (12) 162 (9) 122 (9)
LS mean treatment
difference (95% CI)
80 (37, 124) P < 0.001 29 (22, 80) P Z 0.267a 25 (8, 59) P Z 0.137a 41 (17, 65) P < 0.001
Wm (0e4 h) FEV1, mL on Day 84
LS mean change
from baseline (SE)
235 (16) 162 (16) 208 (17) 167 (17) 230 (12) 201 (12) 225 (8) 181 (8)
LS mean treatment
difference (95% CI)
73 (30, 117) P < 0.001 42 (7, 90) 29 (4, 62) 44 (21, 67) P < 0.001
Wm (0e12 h) FEV1, mL on Day 84
LS mean change from
baseline (SE)
217 (16) 121 (16) 181 (18) 128 (18) 206 (12) 161 (12) 202 (9) 141 (9)
LS mean treatment
difference (95% CI)
96 (51, 141) P < 0.001 53 (2, 104) 46 (12, 79) 61 (37, 85) P < 0.001
Wm (12e24 h) FEV1, mL on Day 84
LS mean change from
baseline (SE)
131 (16) 66 (16) 104 (19) 101 (19) 129 (13) 123 (13) 122 (9) 102 (9)
LS mean treatment
difference (95% CI)
65 (21, 109) P Z 0.004 3 (50, 56) 6 (29, 41) 21 (4, 45) P Z 0.101
Log-rank analysis of time to onset of action, Day 1
Median time to onset,
min
15 30 16 30 15 15 15 19
p-value of treatment
difference
P Z 0.012 P Z 0.018
Change from baseline trough FEV1, mL on Day 85
LS mean change from
baseline (SE)
143 (16) 72 (16) 120 (19) 96 (19) 151 (13) 121 (13) 140 (9) 101 (9)
LS mean treatment
difference (95% CI)
70 (26, 115) P Z 0.002 24 (29, 77) 30 (5, 65) 39 (14, 64) P Z 0.002
CI Z confidence interval; FEV1 Z forced expiratory volume in 1 s; FF Z fluticasone furoate; FP Z fluticasone propionate; LS Z least
squares; SAL Z salmeterol; SE Z standard error; VI Z vilanterol; wm Z weighted mean.
a No inferences (P-values) provided for secondary/other endpoints in Study 2, as primary endpoint did not show an effect.
Once-daily versus twice-daily ICS/LABA in COPD 1175Outcomes of other efficacy analyses are reported in
Table E2. In Studies 1 and 2, no difference was observed
between FF/VI and FP/SAL for occasions of rescue use per
24 h period, 24 h periods free from rescue use over 12
weeks, or pre-dose IC on Day 84.
Safety
Pooled safety data are presented below and summarized in
Table 3, while individual study data are provided in Table
E3. The frequency of AEs was similar between the treat-
ment arms (FF/VI: 27%; FP/SAL: 28%). Headache and
nasopharyngitis were the most frequent events, occurring
in 4e5% of patients in either treatment group. Patients in
the FF/VI and FP/SAL groups experienced 19 and 27 SAEs,
respectively. Across the three studies, two fatal AEs
occurred in patients receiving FF/VI (gastrointestinal
hemorrhage; myocardial infarction with cardiac and respi-
ratory failure) and four occurred in patients receiving FP/
SAL (cardiac failure [two patients]; small cell lung cancer;
cardio-respiratory arrest). None of the fatal events weredeemed by the applicable study investigator to be related
to study treatment. In Study 1, one SAE of atrial fibrillation
in the FP/SAL arm was considered related to study treat-
ment. In Study 2, one SAE of bronchitis in the FF/VI arm was
considered related to study treatment. In Study 3, one SAE
of convulsion and mouth injury in the FF/VI arm and one
SAE of COPD in the FP/SAL arm were considered related to
study treatment.
AEs of special interest, defined as those often associated
with either ICS or LABA therapy, were also assessed (Table
E4). The most prevalent AEs of special interest were local
steroid effects (primarily candidiasis which occurred in 2%
of patients treated with FF/VI and 3% of those who received
FP/SAL) and potential LABA-related cardiovascular effects
(FF/VI: 2%; FP/SAL: 2%).
Six exacerbations occurred in Study 1 (FF/VI: 2; FP/SAL:
4), 15 occurred in Study 2 (FF/VI: 11; FP/SAL: 4), and 40
occurred in Study 3 (FF/VI: 21; FP/SAL: 19). All of these
resolved without sequelae and accounted for five, 13 and
37 withdrawals, respectively. A pneumonia-associated term
was reported in one patient (FF/VI arm) in Study 1 as a
Figure 2 LS mean FEV1 Day 84 change from baseline (pooled
intent-to-treat population). Figures for individual Studies 1e3
are provided in the Online Supplement. FF Z fluticasone
furoate; FP Z fluticasone propionate; LS Z least squares;
SAL Z salmeterol; VI Z vilanterol.
Table 3 Number (and %) of on-treatment AEs and events
of special interest by treatment arm (intent-to-treat
population).
Pooled data
FF/VI
100/25 mcg
n Z 931
FP/SAL
250/50 mcg
n Z 927
On-treatment AEs
Any AE 250 (27) 261 (28)
Headachea 46 (5) 50 (5)
Nasopharyngitisa 44 (5) 38 (4)
Oral candidiasisa 8 (<1) 19 (2)
Back pain 11 (1) 11 (1)
Oropharyngeal candidiasisa 7 (<1) 11 (1)
Any non-fatal serious AE 19 (2) 27 (3)
Any fatal AE 2 (<1) 4 (<1)
Treatment-related AEsb 28 (3) 43 (5)
AEs leading to study
withdrawal
23 (2) 24 (3)
Data for individual Studies 1e3, and for adverse events of
special interest, are provided in the Online Supplement.
AEZ adverse event; FFZ fluticasone furoate; FPZ fluticasone
propionate; SAL Z salmeterol; VI Z vilanterol.
a Preferred terms listed where incidence was 3% of patients
in either treatment group for either study.
b As determined by the investigator.
1176 M.T. Dransfield et al.result of tuberculosis. In Study 2 there were two AEs of
pneumonia in the FF/VI arm (none in the FP/SAL arm);
neither was defined as a SAE, both showed infiltrates on
chest X-ray, and one was deemed potentially related to
study drug by the blinded investigator. In Study 3 there
were four on-treatment AEs of pneumonia in the FF/VI arm
and four in the FP/SAL arm; one pneumonia in the FF/VI
arm and four in the FP/SAL arm were defined as SAEs, and
none were considered related to study treatment. A chest
X-ray was performed on all but one of the patients with
recorded AEs of pneumonia; all of the chest X-rays showed
infiltrates.
No clinically relevant abnormalities were demonstrated
for any laboratory or electrocardiogram assessment, or
urinary cortisol measurement, in any of the studies. In
Study 1 a significant difference in 0e4 h wm pulse rate
(bpm) was observed at Week 12 between FF/VI and FP/SALFigure 3 Cumulative proportions of patients reaching an
increase in FEV1 100 mL from 0 to 4 h on Day 1 (pooled intent-
to-treat population). Figures for individual Studies 1e3 are
provided in the Online Supplement. BD Z twice-daily;
FF Z fluticasone furoate; FP Z fluticasone propionate;
OD Z once-daily; SAL Z salmeterol; VI Z vilanterol.(1.9 [95% CI: 3.3, 0.5], P Z 0.009); no significant dif-
ference was observed in Study 2 (0.8 [95% CI: 2.1, 0.6],
P Z 0.267) or Study 3 (0.1 [95% CI: 1.1, 1.2]; PZ 0.901).
Discussion
The results of these three studies, which directly compared
once-daily FF/VI with twice-daily FP/SAL, demonstrate that
once-daily FF/VI 100/25 mcg improves lung function at
least as much as does twice-daily FP/SAL 250/50 mcg. The
improvement in 24 h lung function observed in Study 1 and
favoring FF/VI 100/25 mcg was both clinically and statisti-
cally significant and was accompanied by a more rapid in-
crease in FEV1. Treatment differences observed in Study 2
and Study 3 numerically favored FF/VI 100/25 mcg over FP/
SAL 250/50 mcg but did not reach clinical or statistical
significance. Although the treatment effect of FF/VI 100/
25 mcg achieved statistical significance in the pooled
analysis, we consider it likely that this is a result of the
increased sample size as the point estimate of the differ-
ence was not felt to be clinically relevant. Both treatments
were well tolerated with generally similar safety profiles.
A careful analysis of all data collected in the three
studies did not reveal any differences between the study
populations, either as a whole or by treatment arm that
could readily explain the differences in outcomes of the
primary endpoint analysis between the studies. The
differing outcomes were also not the result of poor patient
adherence as this was assessed by dose counter and was
excellent in all three studies. It is our conclusion that the
most plausible explanation for the observed differences is
natural study-to-study variability.
Once-daily versus twice-daily ICS/LABA in COPD 1177Adherence during clinical trials is typically high and this
was suggested by the dose counter data from these three
studies. However, it is also well established that adherence
to inhaled therapies in the real-world setting continues to
be sub-optimal though it can be positively influenced by
multiple factors [6], including dosing frequency [19]. Our
findings suggest two related mechanisms through which
once-daily FF/VI may encourage adherence. First, though a
difference in time to onset as assessed by FEV1 was only
observed in Study 1 and in the pooled data, and the dif-
ference between FF/VI and FP/SAL only 4 min, it is possible
that some patients may perceive more rapid lung function
improvement with FF/VI. This is uncertain as there is no
established minimal clinically important difference for this
outcome. However, this possibility is important as the rapid
relief of early morning symptoms of COPD is known to lead
to greater daytime activity levels [20] and in a pan-
European survey of 719 COPD patients 65.8% of patients
felt that “regular therapy with immediate results gives me
reasons for taking regular therapy” [21]. Second, as the
peak bronchodilator effect of FF/VI occurs 4 h after dosing
and because both FF/VI and FP/SAL are impacted by
circadian changes in lung function, the majority of the
additional FEV1 benefit gained with FF/VI was obtained in
the first 12 h which may have potential benefits on activ-
ities of daily living.
Our safety findings indicate similarities between FF/VI
and FP/SAL in terms of overall incidence of AEs across the
three studies, and a low overall rate of SAEs. While the
incidence of cardiovascular AEs of special interest (possibly
related to the LABA) did not differ between treatment
groups, we did observe a higher incidence of local steroid
effects (primarily candidiasis) in patients treated with FP/
SAL compared with FF/VI. Both fluticasone propionate and
fluticasone furoate have been associated with an increased
risk of pneumonia in COPD patients when compared to
treatment with LABA therapy alone [2,3,12]. Though there
were numerically more pneumonias in the FF/VI arms as
compared to the FP/SAL arms (7 vs. 4), the overall rate was
quite low and definitive conclusions about their compara-
tive risk cannot be drawn. It should be noted that the
populations recruited for these trials were not enriched for
exacerbation risk, and as the risks for exacerbation are
similar to those for pneumonia the current trials were not
well suited to address this issue [22].
Determining dose equivalence for FF and FP is a complex
issue as clinical efficacy and toxicity relate to multiple
factors including steroid potency, binding time, and likely,
the pathobiological processes occurring in the underlying
disease (i.e. asthma as opposed to COPD). Although
equivalent data in patients with COPD are lacking, FF is four
times more potent than FP in improving lung function in
subjects with asthma [23,24].
The studies have limitations including the divergent
primary analysis outcomes, which mean definitive conclu-
sions cannot be drawn regarding the lung function advan-
tage conferred by FF/VI relative to FP/SAL. While the post-
hoc pooled analysis showed a statistically significant
treatment difference over the large patient sample, the
observed treatment difference (41 mL) is below the sug-
gested minimal clinically important difference for lung
function [18]. In addition, there was no difference betweentreatment groups in rescue albuterol use, suggesting that
acute episodes of dyspnea were not differentially reduced
in those receiving FF/VI, despite improvements in FEV1.
Due to the lack of patient-reported outcomes, it was not
possible to determine the impact of FF/VI on overall
symptoms and health status, which correlate poorly with
lung function [25]. In addition, the studies were only 12
weeks in duration, and as discussed above did not enroll a
population at high risk for exacerbations, and thus in-
ferences about the relative effects of FF/VI and FP/SAL on
these events and the rates of important AEs (such as
pneumonia) cannot be made.
In conclusion, our findings suggest that once-daily FF/VI
100/25 mcg is at least comparable with and may provide a
greater improvement in lung function than twice-daily FP/
SAL 250/50 mcg, with a comparable safety profile over 12
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